Study identification

EU PAS number

EUPAS104052

Study ID

105577

Official title and acronym

Tecartus Survey: Quantitative Testing of Health Care Professional Knowledge About Tecartus® Risk Minimisation Measures

DARWIN EU® study

No

Study countries

Czechia
France
Germany
Italy
Portugal
Sweden
United Kingdom

Study description

KT-EU-472-5966: The study was a non-interventional, cross-sectional survey of health care professionals (HCPs) based in Europe. The survey was conducted ≥ 12 months after Tecartus® had marketed approval in Europe. The survey was distributed to HCPs who have received training on additional risk minimisation measures (RMMs) and prescribe, handle, dispense, or administer Tecartus or manage patients experiencing Tecartus-related adverse events (AEs). The primary objective of the study was to measure the HCPs awareness and knowledge of RMMs for Tecartus.

Study status

Finalised
Research institutions and networks

Institutions

Gilead Sciences
First published:
12/02/2024
InstitutionPharmaceutical company
Kite

Contact details

Kite Study Director

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Kite, A Gilead Company
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)